Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation

Author's Avatar
May 10, 2022
  • 8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS
  • COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS AND INTEGRATED AI/ML-SUPPORTED DATA ANALYTICS
  • $ 200 M UPFRONT AS WELL AS NEAR-TERM PERFORMANCE-BASED PAYMENTS
  • DEAL POTENTIAL OF $ 5 BN